The activity of pathway-selective estrogen receptor ligands in experimental septic shock.
Estrogen receptors (ER) are widely expressed in multiple genital and nongenital tissues. Upon engagement of these receptors, multiple genes are affected in target tissues via estrogen response elements. Nonsteroidal pathway-selective ER ligands have recently been identified that inhibit NF-kappaB transcriptional activity and are devoid of conventional estrogenic activities on genital tissues. These pathway-selective ligands are potent anti-inflammatory agents in vivo and may prove to be of therapeutic utility in systemic inflammatory states. These pathway-selective ER ligands were tested in the murine listeriosis model, the neutropenic rat model, and the mouse cecal ligation and puncture model. WAY-204688 did not have any significant activity after systemic infection by Listeria monocytogenes. In the neutropenic rat model, WAY-204688 provided a significant survival benefit against an otherwise lethal challenge of Pseudomonas aeruginosa 12.4.4 compared with the control group (88% versus 25% survival; P < 0.05). Preservation of mucosal weight and prevention of histopathologic changes were observed with the administration of WAY-204688. Similar findings were observed in a cecal ligation and puncture model with WAY-204688 and a related compound WAY-169916. These results indicate that oral administration of these pathway-selective ER ligands preserved gastrointestinal barrier function and improve outcome in experimental models of systemic infection and inflammation. These agents may prove to be useful clinically as a novel treatment strategy for severe sepsis.
Opal
Steven M
SM
Memorial Hospital of Rhode Island, Brown Medical School, Providence, Rhode Island 02860, USA. Steven_Opal@brown.edu
Palardy
John E
JE
Cristofaro
Patricia
P
Parejo
Nicolas
N
Jhung
Jhung W
JW
Keith
James C
JC
Chippari
Sue
S
Caggiano
Thomas J
TJ
Steffan
Robert J
RJ
Chadwick
Christopher C
CC
Harnish
Douglas C
DC
D000284:Administration, Oral; D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D008088:Listeriosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D011090:Polyenes / Q000008:administration & dosage*; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D011720:Pyrazoles / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011960:Receptors, Estrogen / Q000819:agonists* / Q000378:metabolism; D012772:Shock, Septic / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism
C113323:32-desmethoxyrapamycin; D016328:NF-kappa B; D011090:Polyenes; D011720:Pyrazoles; D011960:Receptors, Estrogen; C499198:WAY-169916